A randomized, double-blind, parallel group trial of HMR1766 [ataciguat] assessing the efficacy and safety of 3 doses of HMR1766 versus placebo with cilostazol as a calibrator, administered for 26 weeks in patients with peripheral arterial disease fontaine stage II.

Trial Profile

A randomized, double-blind, parallel group trial of HMR1766 [ataciguat] assessing the efficacy and safety of 3 doses of HMR1766 versus placebo with cilostazol as a calibrator, administered for 26 weeks in patients with peripheral arterial disease fontaine stage II.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2012

At a glance

  • Drugs Ataciguat (Primary) ; Cilostazol; Clopidogrel
  • Indications Embolism and thrombosis; Intermittent claudication
  • Focus Therapeutic Use
  • Acronyms ACCELA
  • Sponsors Sanofi
  • Most Recent Events

    • 20 Oct 2009 Actual patient number (553) added as reported by ClinicalTrials.gov.
    • 16 Oct 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 10 Apr 2008 Status change from recruiting to in progress, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top